TWI455928B - 作為TAFIa抑制劑之巨環脲衍生物及磺醯脲衍生物 - Google Patents
作為TAFIa抑制劑之巨環脲衍生物及磺醯脲衍生物 Download PDFInfo
- Publication number
- TWI455928B TWI455928B TW98118477A TW98118477A TWI455928B TW I455928 B TWI455928 B TW I455928B TW 98118477 A TW98118477 A TW 98118477A TW 98118477 A TW98118477 A TW 98118477A TW I455928 B TWI455928 B TW I455928B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- formula
- compound
- group
- twice
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (8)
- 一種式I化合物 與/或式I化合物之立體異構型與/或此等型式依任何比例形式之混合物,與/或式I化合物之生理上可耐受之鹽類,其中X為-C(O)-或-SO2 -,U為氧原子、硫原子、NH、-C(O)-NH-或-(C0 -C4 )-伸烷基-,A為氧原子、硫原子、NH、-C(O)-NH- -NH-C(O)-、-NR2-或-(C0 -C4 )-伸烷基-,V為1)-(C2 -C9 )-伸烷基-,其中伸烷基未經取代或分別獨立經-OH、NH2 或鹵素取代一次、二次或三次,2)-(C1 -C2 )-伸烷基-(C3 -C6 )-環烷基-(C1 -C2 )-伸烷基-,其中環烷基分別獨立經R15取代一次、二次或三次,或3)-(C3 -C9 )-伸烯基-,D為-(C1 -C2 )-伸烷基-,Y為1)共價鍵,2)-(C3 -C12 )-環烷基,其中環烷基分別獨立經R15取代一次、二次或三次, 3)-(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,或4)Het,其中Het意指具有4至15個環原子相接出現在1、2或3個環系中之4-至15-員雜環系,其依環之大小而定,包含1、2、3或4個選自氧、氮或硫中之相同或相異雜原子,且其中Het未經取代或分別獨立經-(C1 -C3 )-烷基、鹵素、-NH2 、-CF3 或-O-CF3 取代一次、二次或三次,R1為1)氫原子,2)-(C1 -C6 )-烷基,3)-(C1 -C6 )-烷基-OH,4)-(C0 -C4 )-烷基-(C3 -C6 )-環烷基,5)-(C1 -C10 )-烷基-O-C(O)-O-R2,6)-(CH2 )r -(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,且r為零、1、2或3之整數,或7)-(CH2 )s -Het,其中Het意指具有4至15個環原子相接出現在1、2或3個環系中之4-至15-員雜環系,其依環之大小而定,包含1、2、3或4個選自氧、氮或硫中之相同或相異雜原子,且其中Het未經取代或分別獨立經R15取代一次、二次或三次,且s為 零、1、2或3之整數,R2為1)-(C1 -C6 )-烷基,2)-(CH2 )r -(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,且r為零、1、2或3之整數,或3)-(C0 -C4 )-烷基-(C3 -C6 )-環烷基,R3為1)-(C2 -C6 )-伸烷基-NH2 ,其中伸烷基未經取代或經鹵素取代一次、二次、三次或四次,2)-(C1 -C4 )-伸烷基-O-(C1 -C4 )-伸烷基-NH2 ,3)-(C1 -C4 )-伸烷基-SO2 -(C1 -C4 )-伸烷基-NH2 ,4)-(C0 -C4 )-伸烷基-Het,其中Het如上述定義,且係經-NH2 取代及經R15取代一次、二次或三次,5)-(C0 -C4 )-伸烷基-(C3 -C8 )-環烷基-NH2 或6)-(C0 -C6 )-伸烷基-環狀胺,R6為1)氫原子,2)-(C1 -C6 )-烷基,其中烷基未經取代或分別獨立經R16取代一次、二次或三次,3)-O-(C1 -C6 )-烷基,其中烷基未經取代或分別獨立經R16取代一次、二次或三次,4)-(C0 -C4 )-伸烷基-Het,其中Het如上述定 義,其中伸烷基與Het未經取代或分別獨立經R16取代一次、二次或三次,5)-(C0 -C4 )-伸烷基-芳基,其中伸烷基與芳基未經取代或分別獨立經R16取代一次、二次或三次,或6)-(C0 -C4 )-伸烷基-(C3 -C8 )-環烷基,其中伸烷基與環烷基未經取代或分別獨立經R16取代一次、二次或三次,R7為氫原子、鹵素或-(C1 -C6 )-烷基,R8為氫原子、鹵素或-(C1 -C6 )-烷基,R9為氫原子、鹵素或-(C1 -C6 )-烷基,R15為氫原子、-(C1 -C4 )-烷基、-O-CF3 、-NH2 、-OH、-CF3 或鹵素,且R16為-O-CF3 、-NH2 、-OH、-CF3 或鹵素。
- 根據申請專利範圍第1項之式I化合物,其中X為-C(O)-或-SO2 -,U為氧原子、硫原子、NH、-C(O)-NH-或-(C0 -C4 )-伸烷基-,A為氧原子、硫原子、NH、-C(O)-NH-或-(C0 -C4 )-伸烷基-,V為1)-(C2 -C9 )-伸烷基-或2)-(C3 -C9 )-伸烯基-,D為-(C1 -C2 )-伸烷基-,Y為1)共價鍵, 2)-(C3 -C12 )-環烷基,其中環烷基分別獨立經R15取代一次、二次或三次,3)-(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,或4)Het,其中Het意指具有4至15個環原子相接出現在1、2或3個環系中之4-至15-員雜環系,其依環之大小而定,包含1、2、3或4個選自氧、氮或硫中之相同或相異雜原子,且其中Het未經取代或分別獨立經-(C1 -C3 )-烷基、鹵素、-NH2 、-CF3 或-O-CF3 取代一次、二次或三次,R1為1)氫原子,2)-(C1 -C6 )-烷基,3)-(C1 -C6 )-烷基-OH,4)-(C0 -C4 )-烷基-(C3 -C6 )-環烷基,5)-(C1 -C10 )-烷基-O-C(O)-O-R2,6)-(CH2 )r -(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,且r為零、1、2或3之整數,或7)-(CH2 )s -Het,其中Het意指具有4至15個環原子相接出現在1、2或3個環系中之4-至15-員雜環系,其依環之大小而定,包含1、2、3或4個選自氧、氮或硫中之相同 或相異雜原子,且其中Het未經取代或分別獨立經R15取代一次、二次或三次,且s為零、1、2或3之整數,R2為1)-(C1 -C6 )-烷基,2)-(CH2 )r -(C6 -C14 )-芳基,其中芳基未經取代或分別獨立經R15取代一次、二次或三次,且r為零、1、2或3之整數,或3)-(C0 -C4 )-烷基-(C3 -C6 )-環烷基,R3為1)-(C2 -C6 )-伸烷基-NH2 ,其中伸烷基未經取代或經鹵素取代一次、二次、三次或四次,2)-(C1 -C4 )-伸烷基-O-(C1 -C4 )-伸烷基-NH2 ,3)-(C1 -C4 )-伸烷基-SO2 -(C1 -C4 )-伸烷基-NH2 ,4)-(C0 -C4 )-伸烷基-Het,其中Het如上述定義,且係經-NH2 取代及經R15取代一次、二次或三次,5)-(C0 -C4 )-伸烷基-(C3 -C8 )-環烷基-NH2 或6)-(C0 -C6 )-伸烷基-環狀胺,R6為1)氫原子,2)-(C1 -C6 )-烷基,其中烷基未經取代或分別獨立經R16取代一次、二次或三次,3)-O-(C1 -C6 )-烷基,其中烷基未經取代或分 別獨立經R16取代一次、二次或三次,4)-(C0 -C4 )-伸烷基-Het,其中Het如上述定義,其中伸烷基與Het未經取代或分別獨立經R16取代一次、二次或三次,5)-(C0 -C4 )-伸烷基-芳基,其中伸烷基與芳基未經取代或分別獨立經R16取代一次、二次或三次,或6)-(C0 -C4 )-伸烷基-(C3 -C8 )-環烷基,其中伸烷基與環烷基未經取代或分別獨立經R16取代一次、二次或三次,R7為氫原子、鹵素或-(C1 -C6 )-烷基,R8為氫原子、鹵素或-(C1 -C6 )-烷基,R9為氫原子、鹵素或-(C1 -C6 )-烷基,R15為氫原子、-(C1 -C4 )-烷基、-O-CF3 、-NH2 、-OH、-CF3 或鹵素,且R16為-O-CF3 、-NH2 、-OH、-CF3 或鹵素。
- 根據申請專利範圍第1或2項之式I化合物,其中X為-C(O)-或-SO2 -,U為氧原子、硫原子、NH、-C(O)-NH-或-(C0 -C4 )-伸烷基-,A為氧原子或-(C0 -C4 )-伸烷基-,V為-(C2 -C8 )-伸烷基-或-(C3 -C6 )-伸烯基-,D為-(C1 -C2 )-伸烷基-, Y為1)共價鍵,2)-(C3 -C6 )-環烷基,其中環烷基分別獨立經R15取代一次、二次或三次,3)-(C6 -C14 )-芳基,其中芳基係選自下列:苯基、萘基、蒽基或茀基,且其中芳基未經取代或分別獨立經R15取代一次、二次或三次,或4)Het,其中Het係選自下列:吖啶基、吖呯基、氮雜環丁烷基、氮雜環丙烷基、苯并咪唑啉基、苯并咪唑基、苯并[1,3]二茂烷基、苯并呋喃基、苯并硫呋喃基、苯并噻吩基、苯并唑基、苯并噻唑基、苯并三唑基、苯并四唑基、苯并異唑基、苯并異噻唑基、咔唑基、4aH-咔唑基、咔啉基、喹唑啉基、喹啉基、4H-喹基、喹啉基、奎寧環基、色滿基、色烯基、噌啉基、十氫喹啉基、二苯并呋喃基、二苯并噻吩基、二氫呋喃[2,3-b]-四氫呋喃基、二氫呋喃基、二茂烷基、二烷基、2H,6H-1,5,2-二噻基、呋喃基、呋咱基、咪唑啶基、咪唑啉基、咪唑基、1H-吲唑基、吲哚啉基、吲哚基、吲哚基、3H-吲哚基、異苯并呋喃基、異色滿基、異吲唑基、異吲哚啉基、異吲哚基、異喹啉基(苯并咪唑基)、異噻唑啶基、2-異噻唑啉基、異噻 唑基、異唑基、異唑啶基、2-異唑啉基、嗎啉基、萘啶基、八氫異喹啉基、二唑基、1,2,3-二唑基、1,2,4-二唑基、1,2,5-二唑基、1,3,4-二唑基、唑啶基、唑基、唑啶基、噻茂烷基、嘧啶基、啡啶基、啡繞啉基、啡基、啡噻基、啡噻基、啡基、酞基、哌基、哌啶基、蝶啶基、嘌呤基、哌喃基、吡基、吡唑啶基、吡唑啉基、吡唑基、嗒基、吡啶并唑基、吡啶并咪唑基、吡啶并噻唑基、吡啶并噻吩基、吡啶基(pyridinyl)、吡啶基(pyridyl)、嘧啶基、吡咯啶基、吡咯啉基、2H-吡咯基、吡咯基、四氫呋喃基、四氫異喹啉基、四氫喹啉基、四氫吡啶基、6H-1,2,5-噻嗒基、1,2,3-噻二唑基、1,2,4-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、噻蒽基、噻唑基、噻吩基、噻吩并咪唑基、噻吩并唑基、噻吩并吡啶基、噻吩并噻唑基、硫嗎啉基、噻吩基、三基、1,2,3-三唑基、1,2,3-三唑基、1,2,4-三唑基、1,2,5-三唑基、1,3,4-三唑基與呫噸基,與其中Het未經取代或分別獨立經-(C1 -C3 )-烷基、鹵素、-NH2 、-CF3 或-O-CF3 取代一次、二次或三次, R1為1)氫原子或2)-(C1 -C4 )-烷基,R3為1)-(C2 -C6 )-伸烷基-NH2 ,其中伸烷基未經取代或經鹵素取代一次、二次、三次或四次,2)-(C1 -C4 )-伸烷基-SO2 -(C1 -C4 )-伸烷基-NH2 或3)-(C0 -C4 )-伸烷基-Het,其中Het如上述定義,且係經-NH2 取代及經R15取代一次、二次或三次,R6為1)氫原子,2)-(C1 -C6 )-烷基,其中烷基未經取代或分別獨立經R16取代一次、二次或三次,3)-O-(C1 -C6 )-烷基,其中烷基未經取代或分別獨立經R16取代一次、二次或三次,4)-(C0 -C4 )-伸烷基-Het,其中Het如上述定義,其中伸烷基與Het未經取代或分別獨立經R16取代一次、二次或三次,5)-(C0 -C4 )-伸烷基-芳基,其中伸烷基與芳基未經取代或分別獨立經R16取代一次、二次或三次,或6)-(C0 -C4 )-伸烷基-(C3 -C6 )-環烷基,其中伸烷基與環烷基未經取代或分別獨立經R16取代一次、二次或三次, R7為氫原子、F或-(C1 -C4 )-烷基,R8為氫原子、F或-(C1 -C4 )-烷基,R9為氫原子、F或-(C1 -C4 )-烷基,R15為氫原子、-(C1 -C4 )-烷基、-O-CF3 、-NH2 、-OH、-CF3 或鹵素,且R16為-O-CF3 、-OH、-CF3 或F。
- 根據申請專利範圍第1或2項之式I化合物,其中X為-C(O)-,U為氧原子,A為氧原子或-(C0 -C4 )-伸烷基-,V為1)-(C2 -C8 )-伸烷基-,其中伸烷基未經取代或分別獨立經-OH、F或Cl取代一或二次,2)-(C1 -C2 )-伸烷基-環丙基-(C1 -C2 )-伸烷基-,其中環丙基經F取代一或二次,或3)-(C3 -C6 )-伸烯基-,D為-(C1 -C2 )-伸烷基-,Y為1)共價鍵或2)苯基,其中苯基未經取代或分別獨立經R15取代一次、二次或三次,R1為1)氫原子或2)-(C1 -C4 )-烷基,R3為1)-(C2 -C6 )-伸烷基-NH2 ,2)-(C1 -C4 )-伸烷基-SO2 -(C1 -C4 )-伸烷基 -NH2 或3)-(C0 -C4 )-伸烷基-吡啶基,其中吡啶基經-NH2 取代及經R15取代一次、二次或三次,R6為1)氫原子,2)-(C1 -C6 )-烷基,3)-CF3 ,4)-(C0 -C4 )-伸烷基-苯基或5)-(C0 -C4 )-伸烷基-(C3 -C6 )-環烷基,R7、R8與R9分別為氫原子,及R15為氫原子、-(C1 -C4 )-烷基、-CF3 或鹵素。
- 根據申請專利範圍第1或2項之式I化合物,其中X為-C(O)-,U為氧原子,A為氧原子或-(C0 -C4 )-伸烷基-,V為-(C2 -C8 )-伸烷基-或-(C3 -C6 )-伸烯基-,D為-(C1 -C2 )-伸烷基-,Y為1)共價鍵或2)苯基,其中苯基未經取代或分別獨立經R15取代一次、二次或三次,R1為1)氫原子或2)-(C1 -C4 )-烷基,R3為1)-(C2 -C6 )-伸烷基-NH2 ,2)-(C1 -C4 )-伸烷基-SO2 -(C1 -C4 )-伸烷基 -NH2 或3)-(C0 -C4 )-伸烷基-吡啶基,其中吡啶基經-NH2 取代或經R15取代一次、二次或三次,R6為1)氫原子,2)-(C1 -C6 )-烷基,3)-CF3 ,4)-(C0 -C4 )-伸烷基-苯基或5)-(C0 -C4 )-伸烷基-(C3 -C6 )-環烷基,R7、R8與R9分別為氫原子,與R15為氫原子、-(C1 -C4 )-烷基、-CF3 或鹵素。
- 根據申請專利範圍第1或2項之式I化合物,其係式I化合物(S)-6-胺基-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((R)-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((R)-9,9-二甲基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-11-側氧基-9-苯基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸, (S)-6-胺基-2-[3-((9S,12R)-9-苯甲基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-9-環己基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-9-乙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-9-甲基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-9-第三丁基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-{3-[(9S,12R)-9-((S)-第二丁基)-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基]脲基}己酸,(S)-6-胺基-2-[3-((13S,16R)-13-異丙基-15-側氧基-2,11-二氧雜-14-氮雜雙環[16.2.2]二十二碳-1(21),18(22),19-三烯-16-基)脲基]己酸,(S)-6-胺基-2-[3-((E)-(9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),4,14(18),15-四烯-12-基)脲基]己酸, (S)-6-胺基-2-[3-((3S,6R)-3-異丙基-5-側氧基-1-氧雜-4-氮雜環十四碳-6-基)脲基]己酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3S,6R)-3-異丙基-5-側氧基-1-氧雜-4-氮雜環十四碳-6-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3S,6R)-3-甲基-5-側氧基-1-氧雜-4-氮雜環十四碳-6-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3S,6R)-3-異丙基-5-側氧基-1-氧雜-4-氮雜環十四碳-6-基)脲基]丙酸乙酯,(S)-3-(6-胺基-吡啶-3-基)-2-[3-((3S,6R)-3-甲基-5-側氧基-1-氧雜-4-氮雜環十四碳-6-基)脲基]丙酸乙酯,(R)-3-(2-胺基乙磺醯基)-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((9S,12R)-9-環丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]丙酸,(S)-6-胺基-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]-6-甲基庚酸, (S)-3-(6-胺基吡啶-3-基)-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1-(17),14(18),15-三烯-12-基)脲基]丙酸乙酯,(S)-2-[3-((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜-雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)-脲基]-3-哌啶-3-基-丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((8S,11R)-8-異丙基-10-側氧基-6-氧雜-1,9,14-三氮雜雙環[11.2.1]十六碳-13(16),14-二烯-11-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3R,6S)-6-異丙基-4-側氧基-8-氧雜-5-氮雜雙環[11.2.2]十七碳-1(16),13(17),14-三烯-3-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((9S,12R)-16-氟-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3S,6R)-3-異丙基-5-側氧基-1,8-二氧雜-4-氮雜環十二碳-6-基)脲基]丙酸,(S)-3-(6-胺基吡啶-3-基)-2-[3-((3S,6R)-3-異丙基-5-側氧基-1,8-二氧雜-4-氮雜環十二碳-6-基)脲基]丙酸甲酯,(S)-6-胺基-2-[3-((3S,6R)-3-異丙基-5-側氧基-1,8-二氧雜-4-氮雜環十二碳-6-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12S)-9-異丙基-11-側氧基 -2,7-二氧雜-10-氮雜雙環-[12.2.2]十八碳-12-基)脲基]己酸,(S)-6-胺基-2-[3-((8S,11R)-8-異丙基-3,10-二側氧基-6-氧雜-2,9-重氮雙環[11.2.2]十七碳-1(16),13(17),14-三烯-11-基)脲基]己酸,(S)-3-(6-胺基-吡啶-3-基)-2-[3-((8S,11R)-8-甲基-3,10-二側氧基-6-氧雜-2,9-重氮-雙環[11.2.2]十七碳-1(16),13(17),14-三烯-11-基)-脲基]-丙酸,(S)-3-(6-胺基-吡啶-3-基)-2-[3-((3S,6R)-3-異丙基-5,9-二側氧基-1-氧雜-4,10-重氮-環十三碳-6-基)-脲基]-丙酸,(S)-6-胺基-2-[3-((9S,12R)-4,5-二羥基-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,(S)-6-胺基-2-[3-((9S,12R)-5-羥基-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)脲基]己酸,3-(6-胺基-吡啶-3-基)-2-[3-((9S,12R)-4,5-二羥基-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜-雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基)-脲基]-丙酸,(S)-6-胺基-2-[((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基胺磺醯基)胺基]己酸或 (S)-6-胺基-2-[((9S,12R)-9-異丙基-11-側氧基-2,7-二氧雜-10-氮雜雙環[12.2.2]十八碳-1(17),14(18),15-三烯-12-基胺磺醯基)胺基]己酸。
- 一種製備根據申請專利範圍第1至6項中一項或多項之式I化合物之方法,其包括a)由式(II)化合物 其中U、R6與R8如式(I)化合物中之定義,與式(III)胺基酸反應 其中R9、A、Y與D如式(I)化合物中之定義,產生式(IV)化合物 其再於環封合複分解反應條件下及隨後氫化所得雙鍵下,轉化成式(V)化合物 其中V為-(C2 -C9 )-伸烷基-或-(C3 -C9 )-伸烯基-,隨後脫除保護基PG,得到式(VI)化合物, 並與式(VII)化合物 其中R3與R7如式(I)化合物中之定義,PG為合適之酯保護基,R3中之氮若適當時可使用合適胺基保護基保護,使用碳醯氯或碳醯氯同等物反應,產生式(VIII)化合物 隨後脫除保護基PG與若適當時出現在R3中氮上之保護基,產生式(I)化合物,或b)由式(IX)化合物 其中U、V、R6與R8如式(I)化合物中之定義,PGa 為合適之羧基保護基,與式(X)胺基酸反應 其中R9、Y與D如式I化合物中之定義,PGb 與PGc 為合適之胺基保護基,產生式(XI)化合物 脫除保護基PGa 與PGb 後,轉化成式(XII)化合物 其利用醯胺偶合法轉化成式(V)化合物,其中A如式I化合物中之定義,隨後脫除保護基,得到式(VI)化合物,並與式(VII)化合物其中R3與R7如式I中之定義,PG為合適之酯保護基,R3中之氮若適當時可使用合適胺基保護基保護,使用碳醯氯或碳醯氯同等物反應,產生式(VIII)化合物,隨後脫除保護基PG及適當時出現在R3中氮上之保護基,產生式(I)化合物,或 c)由式(XIII)化合物 其中U、V、R6與R8如式I化合物中之定義,PGd 為合適之胺基保護基,與式(XIV)胺基酸反應 其中R9、Y與D如式I化合物中之定義,PGc 為合適之胺基保護基與PGe 為合適之羧基保護基,產生式(XV)化合物 脫除保護基PGd 與PGe 後,轉化成式(XVI)化合物 其反應產生式(V)化合物,其中A如式I化合物中之定義,隨後脫除保護基,得到式(VI)化合物,並與式(VII)化合物, 其中R3與R7如式I中之定義,PG為合適之酯保護基,R3中之氮若適當時可使用合適胺基保護基保護,使用碳醯氯或碳醯氯同等物反應,產生式(VIII)化合物,隨後脫除保護基PG及適當時出現在R3中氮上之保護基,產生式(I)化合物,或d)由式XVII化合物 其中U、V、A、Y、D、R6 、R8 與R9 如式I化合物中之定義,與式(V)化合物反應,隨後脫除保護基,得到式(VI)化合物,並與式(VII)化合物,其中R3與R7如式I中之定義,PG為合適之酯保護基,R3中之氮若適當時可使用合適胺基保護基保護,使用碳醯氯或碳醯氯同等物反應,產生式(VIII)化合物,隨後脫離保護基PG及若適當時出現在R3中氮上之保護基,產生式(I)化合物,或e)轉化式(VIIIa)化合物 其中V為-(C3 -C9 )-伸烯基-,形成式(VIIIb)化合物 其中V為-(C3 -C9 )-伸烷基-,其中伸烷基分別獨立經-OH、NH2 或鹵素取代一次、二次或三次,或為-(C1 -C2 )-伸烷基-(C3 -C6 )-環烷基-(C1 -C2 )-伸烷基-,其中環烷基分別獨立經R15取代一次、二次或三次,隨後類似製法a)轉化式(VIIIb)化合物形成式(I)化合物,或f)由式(XVIII)化合物 其中V如式(I)化合物之定義,依序與式(XIX)與(XX)化合物 使用鹼,於極性非質子性溶劑中反應,所得式(XXI)化合物 經脫除保護基PGa,隨後形成肽鏈結,轉化成式(V)化合物,後者再依製法a)反應,產生式(I)化合物,其中R6、R8、R9與A、D、U、V與Y如式(I)化合物之定義,PG為合適保護基,LG為脫離基,如:氯、溴、碘或磺酸酯,或g)由式VI化合物與式(XXII)化合物反應 其中R3與R7如式I化合物中之定義,PG為合適之保護基,產生式(XXIII)化合物 然後轉化成式(I)化合物,或h)分離製法a)、b)、c)、d)、e)、f)或g)製備之式(I)化合物,或因其化學結構產生對映異構型之合適式(I)前體,其係經由與純對映異構性之酸或鹼形成鹽、於對掌性固相上進行層析或利用對掌性純 對映異構性化合物(如:胺基酸)衍化,分離依此方式得到之非對映異構物,並脫除對掌性輔基,產生純對映異構物,或i)單離出製法a)、b)、c)、d)、e)、f)或g)製備之游離型式(I)化合物,或若含有酸或鹼基團時,轉化成生理上可耐受之鹽。
- 一種藥品,其包含有效量之至少一種根據申請專利範圍第1至6項中一項或多項之式I化合物,及醫藥上合適且生理上可耐受之載劑、添加劑與/或其他活性成份與賦形劑。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290520 | 2008-06-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201008917A TW201008917A (en) | 2010-03-01 |
TWI455928B true TWI455928B (zh) | 2014-10-11 |
Family
ID=39800716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW98118477A TWI455928B (zh) | 2008-06-06 | 2009-06-04 | 作為TAFIa抑制劑之巨環脲衍生物及磺醯脲衍生物 |
Country Status (35)
Country | Link |
---|---|
US (5) | US8580777B2 (zh) |
EP (1) | EP2300462B1 (zh) |
JP (1) | JP5531011B2 (zh) |
KR (1) | KR101673886B1 (zh) |
CN (1) | CN102056922B (zh) |
AR (1) | AR072007A1 (zh) |
AU (1) | AU2009254257B2 (zh) |
BR (1) | BRPI0913349A2 (zh) |
CA (1) | CA2726554C (zh) |
CL (1) | CL2009001358A1 (zh) |
CO (1) | CO6321271A2 (zh) |
CR (1) | CR11807A (zh) |
CY (1) | CY1115604T1 (zh) |
DK (1) | DK2300462T3 (zh) |
DO (1) | DOP2010000363A (zh) |
EC (1) | ECSP10010655A (zh) |
ES (1) | ES2494390T3 (zh) |
HK (1) | HK1152936A1 (zh) |
HN (1) | HN2010002558A (zh) |
HR (1) | HRP20140787T1 (zh) |
IL (1) | IL209772A (zh) |
MA (1) | MA32322B1 (zh) |
MX (1) | MX2010012793A (zh) |
NI (1) | NI201000203A (zh) |
NZ (1) | NZ589671A (zh) |
PL (1) | PL2300462T3 (zh) |
PT (1) | PT2300462E (zh) |
RU (1) | RU2502736C2 (zh) |
SI (1) | SI2300462T1 (zh) |
SV (1) | SV2010003747A (zh) |
TW (1) | TWI455928B (zh) |
UA (1) | UA104002C2 (zh) |
UY (1) | UY31868A (zh) |
WO (1) | WO2009146802A1 (zh) |
ZA (1) | ZA201007719B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ589671A (en) | 2008-06-06 | 2012-03-30 | Sanofi Aventis | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
CA2727925A1 (en) | 2008-06-23 | 2009-12-30 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
JP5823066B2 (ja) * | 2012-03-06 | 2015-11-25 | ファイザー・インク | 増殖性疾患の治療のための大環状誘導体 |
US9834527B2 (en) * | 2013-06-10 | 2017-12-05 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
CN103755852B (zh) * | 2013-12-18 | 2015-12-09 | 湖北大学 | 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途 |
CN106631832A (zh) * | 2016-10-08 | 2017-05-10 | 帕潘纳(北京)科技有限公司 | 一种氨基醚类化合物的制备方法 |
US10411291B2 (en) * | 2017-03-22 | 2019-09-10 | Nanotek Instruments, Inc. | Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030080A1 (en) * | 1996-02-20 | 1997-08-21 | Ortho Pharmaceutical Corporation | Macrocyclic peptides useful in the treatment of thrombin related disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU667995B2 (en) | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
US6353023B1 (en) | 1997-08-28 | 2002-03-05 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
DE60042585D1 (de) * | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken |
DE102004020186A1 (de) * | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
WO2008067909A2 (de) | 2006-12-06 | 2008-06-12 | Sanofi-Aventis | Harnstoff- und sulfamidderivate als inhibitoren von tafia |
NZ589671A (en) | 2008-06-06 | 2012-03-30 | Sanofi Aventis | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
-
2009
- 2009-05-22 NZ NZ589671A patent/NZ589671A/en not_active IP Right Cessation
- 2009-05-22 PL PL09757185T patent/PL2300462T3/pl unknown
- 2009-05-22 KR KR1020107027133A patent/KR101673886B1/ko active IP Right Grant
- 2009-05-22 BR BRPI0913349A patent/BRPI0913349A2/pt not_active Application Discontinuation
- 2009-05-22 MX MX2010012793A patent/MX2010012793A/es active IP Right Grant
- 2009-05-22 AU AU2009254257A patent/AU2009254257B2/en not_active Ceased
- 2009-05-22 CN CN2009801210767A patent/CN102056922B/zh not_active Expired - Fee Related
- 2009-05-22 SI SI200931001T patent/SI2300462T1/sl unknown
- 2009-05-22 ES ES09757185.5T patent/ES2494390T3/es active Active
- 2009-05-22 RU RU2010154089/04A patent/RU2502736C2/ru not_active IP Right Cessation
- 2009-05-22 EP EP09757185.5A patent/EP2300462B1/de active Active
- 2009-05-22 WO PCT/EP2009/003650 patent/WO2009146802A1/de active Application Filing
- 2009-05-22 UA UAA201100191A patent/UA104002C2/ru unknown
- 2009-05-22 PT PT09757185T patent/PT2300462E/pt unknown
- 2009-05-22 DK DK09757185T patent/DK2300462T3/da active
- 2009-05-22 US US12/996,460 patent/US8580777B2/en not_active Expired - Fee Related
- 2009-05-22 JP JP2011512000A patent/JP5531011B2/ja not_active Expired - Fee Related
- 2009-05-22 CA CA 2726554 patent/CA2726554C/en not_active Expired - Fee Related
- 2009-06-04 AR ARP090102005 patent/AR072007A1/es unknown
- 2009-06-04 UY UY31868A patent/UY31868A/es not_active Application Discontinuation
- 2009-06-04 CL CL2009001358A patent/CL2009001358A1/es unknown
- 2009-06-04 TW TW98118477A patent/TWI455928B/zh not_active IP Right Cessation
-
2010
- 2010-10-28 ZA ZA2010/07719A patent/ZA201007719B/en unknown
- 2010-11-22 NI NI201000203A patent/NI201000203A/es unknown
- 2010-11-23 CR CR11807A patent/CR11807A/es not_active Application Discontinuation
- 2010-11-23 DO DO2010000363A patent/DOP2010000363A/es unknown
- 2010-11-30 MA MA33377A patent/MA32322B1/fr unknown
- 2010-12-01 CO CO10151420A patent/CO6321271A2/es active IP Right Grant
- 2010-12-02 EC ECSP10010655 patent/ECSP10010655A/es unknown
- 2010-12-02 SV SV2010003747A patent/SV2010003747A/es unknown
- 2010-12-03 HN HN2010002558A patent/HN2010002558A/es unknown
- 2010-12-05 IL IL209772A patent/IL209772A/en not_active IP Right Cessation
-
2011
- 2011-07-07 HK HK11107008A patent/HK1152936A1/zh not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,339 patent/US8722655B2/en not_active Expired - Fee Related
-
2014
- 2014-03-26 US US14/226,132 patent/US9126955B2/en not_active Expired - Fee Related
- 2014-08-08 CY CY20141100631T patent/CY1115604T1/el unknown
- 2014-08-20 HR HRP20140787AT patent/HRP20140787T1/hr unknown
-
2015
- 2015-07-28 US US14/811,364 patent/US9309207B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 US US15/057,920 patent/US9688645B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030080A1 (en) * | 1996-02-20 | 1997-08-21 | Ortho Pharmaceutical Corporation | Macrocyclic peptides useful in the treatment of thrombin related disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI455928B (zh) | 作為TAFIa抑制劑之巨環脲衍生物及磺醯脲衍生物 | |
CA2780403C (en) | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | |
ES2951829T3 (es) | Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres | |
AU2008245082B8 (en) | Aminodihydrothiazine derivatives substituted with a cyclic group | |
ES2671502T3 (es) | Proceso novedoso para preparar compuestos para su uso en el tratamiento de cáncer | |
ES2616812T3 (es) | Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa | |
IL272667B (en) | Imidazo-pyridine compounds as pad inhibitors | |
US9856264B2 (en) | Isoquinolinesulfonyl derivative as RHO kinase inhibitor | |
CN113557235A (zh) | 用于药物治疗的杂环化合物 | |
CN107531614B (zh) | 德罗格韦的制备方法 | |
WO2013066831A1 (en) | Compounds and methods | |
CA2918451A1 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
CA2606538A1 (en) | 3 -m0n0- and 3 , 5-disubstituted piperidine derivatives as renin inhibitors | |
JP2011521981A5 (zh) | ||
ES2956090T3 (es) | Inhibidores de bencimidazol de enzimas PAD | |
ES2573698T3 (es) | Derivados bicíclicos útiles como inhibidores de DPP-1 | |
JP2015528438A (ja) | 新しい抗菌化合物 | |
ES2634999T3 (es) | Nuevos compuestos antibacterianos | |
TW201706254A (zh) | 含氮雜環化合物之製造方法及其中間體 | |
JP2013121958A (ja) | 2−(2−アミノ−ピリミジン−4−イル)−1h−インドール−5−カルボン酸誘導体の製造方法 | |
JP2008542315A5 (zh) | ||
ES2367811T3 (es) | Compuestos heterocíclicos. | |
TW201011042A (en) | [1,2,4]thiadiazine 1,1-dioxide compounds | |
WO2021158936A1 (en) | Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | |
US20040266796A1 (en) | Convergent processes for the synthesis of a GARFT inhibitor containing a methyl substituted thiophene core and intermediates therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |